In this Issue  by Rees, Jonathan & Ha, Tom
In this Issue
Prepared by Jonathan Rees and Tom Ha, University of Edinburgh
One Person: Two Skinss
The intellectual core of dermatology is to explain the biologic basis
for the patterns rashes make. In some instances the reason for a
particular order is quite clear; the external insult that leads to
contact allergic eczema, or the photo-distribution of the rash
triggered by ultraviolet radiation. Perhaps the most enigmatic of all
have been the patterns ®rst described by Blaschko over a century
ago. Initially confused with dermatomal patterns, and hence a
neurologic basis, we can now think of these rashes as highlighting
the natural patterns of keratinocyte migration. The somatic
mutation merely acting as a tracer ± Nature's own green ¯uorescent
protein so to speak ± that reveals and records the developmental
path cells have taken.
Ever since the molecular basis for some of the keratin disorders
was elucidated and the keratin mutations identi®ed by Elaine Fuchs
in mosaic epidermolytic hyperkeratoses, a sensible research maxim
has been that all generalized rashes will exist in mosaic forms.
Sakuntabhai and colleagues (p. 1144) now add Darier's disease to
the ever increasing list. Darier's disease we now know to be
secondary to mutations in a sarco/endoplasmic reticulum Ca2+
ATPase. The authors now show that patients with segmental or
focal nevi with the clinical and pathologic features of Darier's
disease show somatic mutations in the same gene. Such patients are
therefore genetic mosaics. The clinical lesson being that if the
mosaicism affects the germs cells then germline transmission is
possible.
The presence of such diseases should alert us to an even more
interesting hypothesis. Many germline mutations will be embry-
onically lethal; we will never see the full cutaneous phenotype. On
the other hand, as postzygotic events, con®ned to the skin, such
mutations may have a phenotype. Focal rashes, or rashes following
Blaschko's lines, with no obvious generalized equivalent, may
provide an insight into the action of such embryonically lethal
genes: Nature's own Cre-Lox constructs!
One Individual: Four Cancers
That carcinogenesis is a multistage process involving many genetic
events is so much part of the mainstream and rolls so easily off the
tongue that we often forget how great is the paucity of evidence
linking each genetic change with the various behaviors we see in
the clinic. Indeed, following on from the pioneering work of Bert
Vogelstein on colorectal cancer, despite the large number of studies
describing correlations between genetic change and morphology or
tumor behavior in groups of patients, a persistent criticism is that
such studies fail to take into account the limitations of cross-
sectional analyzes in different persons with different genetic back-
grounds (of both person and tumor).
The present study from Popp et al (p. 1095) addresses this issue in
a singular way. The authors have managed to sample tumors and
establish cell lines from the same individual with squamous tumors
at various clinico-pathologic stages. They present thorough
molecular analyzes using FISH and comparative genomic hybridi-
zation as well as sequencing and RT-PCR studies. An additional
bonus to this landmark study is that, unusually for skin
malignancies, the lines are wild-type for p53. This makes the
described cells lines all the more interesting and valuable for
studying what turns a normal keratinocyte into a malignant one. I
predict the lines will be much sought after and may become as well
known as the correspondence's earlier (jointly with Norbert
Fusenig) HaCaT cell line!
One Agent: How Many Pathways?
Imagine how many fewer scientists would be gainfully employed if
ultraviolet radiation (UVR) acted through one receptor and one
simple signaling pathway. The paper from Scholzen and colleagues
(p. 1021) reminds us how far from the truth we are in cataloguing,
let alone understanding the myriad pathways that UVR exerts on
skin. And what galls most is the way that Nature seems to have
placed false trails all around and uses the same molecules in
completely different physiologic pathways. In this study the authors
show that the human melanocortin 1 receptor (MC1R), the
receptor for the tridecapeptide a-melanocyte stimulating hormone
(a-MSH), better thought of as a rate limiting step in melanogenesis,
may serve a broader physiologic purpose. They con®rm that
MC1R is present on endothelial cells in culture and argue that
these cells possess the necessary machinery including expression of
POMC and the relevant proconvertases to generate POMC
peptides. Irradiation with UVR leads to increased proconvertase
expression (as do Il-1b and a-MSH itself) and the authors argue
that in turn the resulting generation of a-MSH may play a role in
the modulation of skin in¯ammation. Can anybody now imagine
thinking of UVR as a designer drug?
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One Symptom; Two New Technologies
Technology seems to drive biology, perhaps even more than ideas.
Two papers in the present Journal use new techniques to study old
problems.
Itch is the major symptom of skin disease and consequently ± one
is tempted to add facetiously ± ignored by all serious researchers.
The problem is how to get a handle on this complaint, how to turn
this most ubiquitous of symptoms into a tractable scienti®c
problem. The papers by Darsow and colleagues (p. 1029) and
Weidner and colleagues (p. 1015) offer potential insights.
Darsow et al take advantage of advances in imaging and use PET
scanning to study the correlates of experimentally induced itching.
The brain areas highlighted (by activation) include as one would
expect some motor and sensory areas, but as the authors conclude
are perhaps more complex and widespread than many might have
at ®rst thought. Although the study by Darsow is not the ®rst to use
this approach (see J Neuroscience 1997; 17:8003±8008) it is a
welcome addition.
Also related to itch, but more to the point the absence of itch, in
the this issue Schmelz and coworkers have used microdialysis to
study the acute effects of substance P and CGRP in skin.
Microdialysis, after much use by neuroscientists, is increasingly
becoming a powerful technique in understanding skin physiology.
It offers the real opportunity to measure the genuine physiologic
levels of key mediators in vivo and of course to apply pharmacologic
agents experimentally in a controlled way with the minimum (as
the authors point out) of experimental artefact due to trauma.
These authors report that despite causing vasodilation, neither
substance P nor CGRP activate nocioreceptors (i.e., they failed to
produce itch or pain). The authors suggest that delivery via
microdialysis catheter may avoid previous problems associated with
pain from intradermal injections confounding studies of neuropep-
tide action. If the authors' conclusions are correct then some of the
present neuropeptide antagonist drugs may turn out to be less useful
than many think, and yet again, the textbooks need revision.
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